Spots Global Cancer Trial Database for Irradiated Donor Lymphocytes in Treating Patients With Metastatic Kidney Cancer

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Irradiated Donor Lymphocytes in Treating Patients With Metastatic Kidney Cancer

Official Title: Immunotherapy for Patients With Renal Cell Carcinoma

Study ID: NCT00176501

Conditions

Kidney Cancer

Interventions

therapeutic allogeneic lymphocytes

Study Description

Brief Summary: RATIONALE: When irradiated donor lymphocytes are infused into the patient they may help the patient's immune system kill tumor cells. PURPOSE: This phase II trial is studying the side effects and how well giving irradiated donor lymphocytes works in treating patients with metastatic kidney cancer.

Detailed Description: OBJECTIVES: * Determine the response rate in patients with metastatic renal cell carcinoma treated with HLA-partially matched related donor lymphocytes. * Determine the rate and kinetics of clinical/radiological response in patients treated with this regimen. * Determine the toxicity of this regimen in these patients. * Determine the rates of graft-vs-host disease in patients treated with this regimen. OUTLINE: Patients receive irradiated donor lymphocytes IV over 1 hour on day 0. Treatment repeats every 8-16 weeks for up to 6 donor lymphocyte infusions in the absence of disease progression or unacceptable toxicity. Blood is collected periodically for research studies, including immunophenotypic analysis of cells and assay for cytotoxic T-lymphocytes and natural killer-cell activity against target cells. After completion of study treatment, patients are followed for 60 days. PROJECTED ACCRUAL: A total of 35 patients will be accrued for this study.